Efficacy and Safety of a Fixed or a Flexible Supplementary Insulin Therapy in Type 2 Diabetes

Inclusion Criteria: * Type 2 Diabetes for more than 6 months * Treatment with 1 or more oral anti-diabetic drugs or insulin, or a combination of these for more than 3 months * Body Mass Index (BMI) less than or equal to 40 kg/m2 * HbA1c 7.0-11.0% Exclusion Criteria: * Treatment with short acting insulin(s) for longer than 10 days * Current treatment with TZDs. A TZD medication must be stopped at least 14 days before the randomization * Proliferative retinopathy or maculopathy requiring acute or laser treatment within the last 6 months